Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
Completed · Phase 1 · NCT06118151
Conditions: Influenza, Influenza Immunization
At a glance
- Research payments reported, 2025
- $2,968
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 388
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- Influenza Hemagglutinin mRNA vaccine (biological), Quadrivalent Recombinant Influenza Vaccine (biological)
- Dates
- Started 2022-04-11; completion 2023-02-17
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different dose levels of messenger ribonucleic acid (mRNA) vaccine encoding influenza hemagglutinin compared to an active control quadrivalent recombinant influenza vaccine (RIV4) in adults 18 years of age and older. Study details include: Study Duration: approximately 6 months Treatment Duration: 1 injection of mRNA vaccine encoding influenza hemagglutinin encoding influenza hemagglutinin or control. Visit Frequency: Screening visit, Day 01, Day 02, Day 03, Day 09, Day 29, Day 91, Day 181
From ClinicalTrials.gov, last updated 2023-11-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $2,968 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research Advantage Inc $2,968
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.